Abstract |
The aim of this study was to evaluate the safety and the biological effects of interleukin (IL-1 alpha) in patients' with recurrent ovarian carcinoma treated with carboplatin. In this phase I study, IL-1 alpha was administered by a continuous intravenous infusion at doses ranging 0.1-10 micrograms/m2 every 24 h for 4 days (96 h) 3 weeks before the first dose of carboplatin (400 mg/m2) in patients with potentially platinum-sensitive ovarian cancer. The maximum tolerated dose was 3 microgram/m2/day. Dose-limiting effects at 10 micrograms/m2/day were fever, chills, hypotension and fluid retention. Minor but objective antitumour effects were observed in 2 of 18 patients. 4 patients (including 1 with a minor response) had a decrease of the CA-125 serum level ranging from 33 to 39%. The trial design precluded evaluation of the duration of response to single-agent IL-1 alpha. Based on this trial design, there is evidence of minor antitumour effect to a single course of IL-1 alpha dose given prior to chemotherapy.
|
Authors | C F Verschraegen, A P Kudelka, W Termrungruanglert, C G de Leon, C L Edwards, R S Freedman, J J Kavanagh, S Vadhan-Raj |
Journal | European journal of cancer (Oxford, England : 1990)
(Eur J Cancer)
Vol. 32A
Issue 9
Pg. 1609-11
(Aug 1996)
ISSN: 0959-8049 [Print] England |
PMID | 8911126
(Publication Type: Clinical Trial, Clinical Trial, Phase I, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- CA-125 Antigen
- Interleukin-1
|
Topics |
- Adult
- Aged
- CA-125 Antigen
(blood)
- Female
- Humans
- Interleukin-1
(adverse effects, therapeutic use)
- Lymphatic Metastasis
- Middle Aged
- Neoplasm Recurrence, Local
- Ovarian Neoplasms
(therapy)
|